Vivesto AB news
The process of recruiting a permanent CEO has been accelerated. Christer Nordstedt will continue in his current role until 30 November 2022 and will thereafter remain as senior advisor to Vivesto on a consultancy basis.
Christer Nordstedt has been acting CEO since 21 July 2022.
Peter Zonabend, Chairman of the Board of Vivesto, said: “We would like to thank Christer for his efforts during his time as acting CEO of Vivesto, and we are pleased that Christer, with his extens
On November 21, 2022, Vivesto announced that Erik Kinnman was appointed as the new CEO of Vivesto, effective no later than May 20, 2023. Vivesto has today agreed with Christer Nordstedt that he will remain in his current position as acting CEO of Vivesto on a part-time basis until Erik Kinnman takes office.
"We are very pleased that Christer can remain in his role as acting CEO of Vivesto. During the short time he has been with us, Christer has demonstrated his broad competence
In accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB’s (”Vivesto”) Annual General Meeting on 25 May 2022, it is hereby announced that the Nomination Committee for the 2023 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2022.
The Nomination Committee for the 2023 Annual General Meeting comprises the following members:
This means that the distribution activities for Paclical (Apealea) in Russia and the Commonwealth of Independent States (CIS) will be paused until further notice.
The wind down of Vivesto’s activities in Russia means that a write down of SEK 44.6 million will be carried out, equal to the net book value of the capitalized development costs for Paclical after amortization as of June 30, 2022. The write down will be a cost in the income statement and have a negative impact on the e
Vivesto AB (“Vivesto” or the “Company”), an oncology-focused specialty pharmaceutical company, hereby announces that the Board of Directors of the Company has today agreed with the Company’s CEO, Francois Martelet, to mutually terminate his employment. Pursuant to the agreement, Francois’ employment will end on 21 July 2022.
Vivesto has commenced the search for a new CEO.
Francois Martelet has been CEO